Literature DB >> 2256442

Immunosuppressive treatment of patients with amyotrophic lateral sclerosis.

L Werdelin1, G Boysen, T S Jensen, P Mogensen.   

Abstract

Documented treatment for amyotrophic lateral sclerosis (ALS) is not available. Several studies have suggested an immunological etiology and an effect on the course of disease, when ALS-patients were treated with immunosuppressants. The aim of the present study was to evaluate the effect of immunosuppressive therapy in ALS-patients comparing the course of disease in treated patients and in historic controls with ALS; 21 patients were included in the study, 17 men and 4 women. Median age at admission was 54 years for men and 61 years for women. 5 had progressive bulbar palsy, 7 both upper and lower motor neuron affections and 9 progressive muscular atrophy. Patients were treated with prednisolone and azathioprine for 1 year and examined regularly; 12 were treated and followed for more than a year. No definite difference between survival in treated patients and their controls was found.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2256442     DOI: 10.1111/j.1600-0404.1990.tb01602.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  17 in total

Review 1.  Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis.

Authors:  Kristopher G Hooten; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

2.  Impact of peripheral immune status on central molecular responses to facial nerve axotomy.

Authors:  D O Setter; E M Runge; N D Schartz; F M Kennedy; B L Brown; K P McMillan; W M Miller; K M Shah; M M Haulcomb; V M Sanders; K J Jones
Journal:  Brain Behav Immun       Date:  2017-10-10       Impact factor: 7.217

Review 3.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

Review 4.  Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis.

Authors:  Sebastiano Giuseppe Crisafulli; Simona Brajkovic; Maria Sara Cipolat Mis; Valeria Parente; Stefania Corti
Journal:  Mol Neurobiol       Date:  2017-04-28       Impact factor: 5.590

5.  Spinal but not cortical microglia acquire an atypical phenotype with high VEGF, galectin-3 and osteopontin, and blunted inflammatory responses in ALS rats.

Authors:  Maria Nikodemova; Alissa L Small; Stephanie M C Smith; Gordon S Mitchell; Jyoti J Watters
Journal:  Neurobiol Dis       Date:  2013-11-19       Impact factor: 5.996

Review 6.  The Role of immune and inflammatory mechanisms in ALS.

Authors:  P A McCombe; R D Henderson
Journal:  Curr Mol Med       Date:  2011-04       Impact factor: 2.222

7.  CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis.

Authors:  Matthew C Evans; Pieter J Gaillard; Marco de Boer; Chantal Appeldoorn; Rick Dorland; Nicola R Sibson; Martin R Turner; Daniel C Anthony; Helen B Stolp
Journal:  Acta Neuropathol Commun       Date:  2014-06-13       Impact factor: 7.801

8.  Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis.

Authors:  David J Graber; William F Hickey; Brent T Harris
Journal:  J Neuroinflammation       Date:  2010-01-28       Impact factor: 8.322

9.  Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis.

Authors:  Claudia Figueroa-Romero; Junguk Hur; Diane E Bender; Colin E Delaney; Michael D Cataldo; Andrea L Smith; Raymond Yung; Douglas M Ruden; Brian C Callaghan; Eva L Feldman
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.752

10.  Tocilizumab is safe and tolerable and reduces C-reactive protein concentrations in the plasma and cerebrospinal fluid of ALS patients.

Authors:  Carol Milligan; Nazem Atassi; Suma Babu; Richard J Barohn; James B Caress; Merit E Cudkowicz; Armineuza Evora; Gregory A Hawkins; Marlena Wosiski-Kuhn; Eric A Macklin; Jeremy M Shefner; Zachary Simmons; Robert P Bowser; Shafeeq S Ladha
Journal:  Muscle Nerve       Date:  2021-06-24       Impact factor: 3.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.